Related Experiment Video
Updated: Sep 17, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
A Novel Three Small Molecule Inhibitor Combination Therapy For Prostate Cancer
Ummuhan Demir1,2, Hilal Badoglu2,3, Irem Nur Cetin2,4
1Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istanbul Medeniyet University, Istanbul, Turkiye ummuhan.demir@medeniyet.edu.tr.
Background/Aim:
Prostate cancer is common in elderly men. Single treatment options are inadequate for effective therapy. In this study, three small-molecule inhibitors targeting three different pathways related to stemness were combined to obtain an effective antiproliferative effect on prostate cancer cell lines. These small molecules and their corresponding target were: KJ-Pyr-9 as an inhibitor of MYC proto-oncogene bHLH transcription factor (MYC); pyrvinium pamoate as an inhibitor of WNT; and glasdegib as an inhibitor of Sonic Hedgehog (SHH), which induces stem cell properties of cells.
Materials And Methods:
Firstly, the half-maximal inhibitory concentration (IC50) and IC25 doses of each drug against the PC-3 cell line and dose optimization for combination of all three drugs were determined. PNT1A cells were used as a healthy control. 3D culture and scratch assays were applied to test efficiency of combined drug treatment.
Results:
According to 2D culture results, the combination was synergistic in PC-3 while its effect was minimal in PNT1A. The combined treatment diminished both viability and size of 3D spheroids of PC-3 and LNCaP cells. In addition, the combined treatment reduced the migratory potential of PC-3 and LNCaP cells.
Conclusion:
The combined treatment proposed in this study is novel and promising in overcoming drug resistance and side-effects of single agents and may herald a new era in the treatment paradigm for prostate cancer.
Insights
This study combined three small-molecule inhibitors targeting MYC, WNT, and SHH pathways to effectively reduce prostate cancer cell proliferation and migration. The novel combination therapy shows promise for overcoming drug resistance in prostate cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Prostate cancer is a prevalent malignancy in elderly men, often requiring multifaceted therapeutic strategies.
- Current single-agent treatments for prostate cancer exhibit limitations in efficacy and can lead to resistance.
- Targeting stemness pathways, including MYC, WNT, and Sonic Hedgehog (SHH), presents a potential approach to combat prostate cancer.
Purpose of the Study:
- To investigate the antiproliferative effects of a novel combination therapy targeting three distinct stemness-related pathways in prostate cancer.
- To evaluate the efficacy of combining KJ-Pyr-9 (MYC inhibitor), pyrvinium pamoate (WNT inhibitor), and glasdegib (SHH inhibitor) on prostate cancer cell lines.
Main Methods:
- Determined half-maximal inhibitory concentration (IC50) and IC25 doses for individual drugs and optimized combination doses in PC-3 cells.
- Utilized 2D and 3D cell cultures, including PC-3, LNCaP (prostate cancer), and PNT1A (healthy control) cell lines.
- Employed scratch assays to assess the impact of the combined treatment on cell migration.
Main Results:
- The drug combination demonstrated synergistic antiproliferative effects in PC-3 cells, with minimal impact on healthy PNT1A cells.
- Combined treatment significantly reduced the viability and size of 3D spheroids derived from PC-3 and LNCaP cells.
- The combination therapy markedly decreased the migratory potential of PC-3 and LNCaP prostate cancer cells.
Conclusions:
- This novel combination therapy targeting MYC, WNT, and SHH pathways offers a promising strategy for prostate cancer treatment.
- The approach has the potential to overcome drug resistance and mitigate side effects associated with single-agent therapies.
- This study may pave the way for a new era in prostate cancer treatment paradigms.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...